Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447009 | 0.93 | LMNA (0.44) | MAP4K4LMNAL3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL28581458 | 0.85 | LMNA (0.52) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL31117363 | 0.83 | CTSK (0.44) | MAP4K4CTSKCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2459892 | 0.82 | MAP4K4 (0.57) | MAP4K4CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL29730148 | 0.82 | HSD11B1 (0.42) | MAP4K4CTSKMMP13 | |
| SCHEMBL16468401 | 0.82 | MAP4K4 (0.42) | MAP4K4LMNAL3MBTL1CTSKALDH1A1 | |
| SCHEMBL10188237 | 0.81 | OPRM1 (0.47) | LMNACTSKALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL2561818 | 0.79 | MAPT (0.48) | MAP4K4LMNAL3MBTL1CTSKALDH1A1 | |
| SCHEMBL31117822 | 0.79 | MAP4K4 (0.61) | MAP4K4CTSKCYP1A2CYP2C19MEN1 | |
| SCHEMBL2557458 | 0.78 | MAPT (0.47) | MAP4K4LMNAL3MBTL1CTSKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7183293-B2 | Ether derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161681-A1 | ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PDE4A, PDE4B, PDE4D | MAP4K4 1042/4885LMNA 4413/4885L3MBTL1 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.